Author(s): Nour Abboud, Rana Makhous

Email(s): nourabboud1234@gmail.com , rana.makhous@tishreen.edu.sy

DOI: 10.52711/0974-360X.2022.00445   

Address: Nour Abboud1*, Rana Makhous2
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
2Professor in the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tishreen University, Latakia, Syria.
*Corresponding Author

Published In:   Volume - 15,      Issue - 6,     Year - 2022


ABSTRACT:
Statins are HMG-CoA reductase inhibitors, which are widely used as cholesterol-lowering drugs to treat hypercholesterolemia. They are essential in the primary and secondary prevention of CVDs. They are also well tolerated drugs, although there might be some adverse reactions, particularly the new onset of T2DM. As DM, impaired fasting glucose and pre-diabetes are significant cardiovascular risk factors, the purpose of the current work was to study the effects of some statins (pravastatin and pitavastatin) on glucose blood levels in non-diabetic and diabetic mice. Non-diabetic and diabetic female albino mice were treated with pravastatin and pitavastatin once a day for 28 days. Diabetes was induced using alloxan monohydrate (160mg/Kg body weight). Both body weight and fasting blood glucose were measured. IGTT was performed before and after drug treatment. There was no significant statistical difference in body weight between groups before and after 4 weeks of treatment. In addition, we didn’t find any marked change in fasting glucose concentrations of the treated groups in comparison to the control groups of each mouse model. No statistically significant difference was reported when we compared glucose values of IGTT before treatment and at the end of the study for each of the non-diabetic groups. Furthermore, no significant difference was recognized in IGTT results within the diabetic groups before and after drug administration, except for the pravastatin group, which showed a significant decrease in minute 30 of IGTT. We concluded that pravastatin may improve glucose intolerance in diabetic patients. Pitavastatin also may not affect the glycemic status in both models. Both drugs didn’t adversely affect fasting glucose levels in the two mouse models. These findings suggest that pravastatin and pitavastatin may be considered as good choices for patients with DM and hypercholesterolemia.


Cite this article:
Nour Abboud, Rana Makhous. The effect of some statins on Glucose blood levels in experimental animals. Research Journal of Pharmacy and Technology. 2022; 15(6):2661-6. doi: 10.52711/0974-360X.2022.00445

Cite(Electronic):
Nour Abboud, Rana Makhous. The effect of some statins on Glucose blood levels in experimental animals. Research Journal of Pharmacy and Technology. 2022; 15(6):2661-6. doi: 10.52711/0974-360X.2022.00445   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-6-49


REFERENCES:
1.    Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med. 1998; 339(19):1349-57.doi.org/10.1056/NEJM199811053391902
2.    Shepherd J. Cobbe S. M. Ford I. Isles C. G. Lorimer A. R. MacFarlane P. W. McKillop J. H. et al Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7.doi.org/10.1056/NEJM199511163332001
3.    Sirtori C. R. The Pharmacology of Statins. Pharmacol Res. 2014; 88:3-11.doi.org/10.1016/j.phrs.2014.03.002
4.    Liao J. K. Laufs U. Pleiotropic Effects of Statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118.doi.org/10.1146/annurev.pharmtox.45.120403.095748
5.    Ashna A.  Jeena S.  Vidhya P.  Venkateswaramurthy N. Sambathkumar R. Statins: Pleiotropic Effect. Research Journal of Pharmacy and Technology. 2016; 9(7):977-81.doi.org/
6.    Lekshmi R. Shanmugasundaram P. Neuroprotective Properties of Statins. Research Journal of Pharmacy and Technology. 2018; 11(8):3581-84.doi.org/
7.    Gupta S.  Jain R. Kapur S. Statins: A Review of Wonder Drug from Fungus. Research Journal of Pharmacy and Technology. 2014; 7(10):1201-07.doi.org/
8.    Zhou Q. Liao J. K. Pleiotropic Effects of Statins. - Basic Research and Clinical Perspectives. Circ J. 2010; 74(5):818-26.doi.org/10.1253/circj.cj-10-0110
9.    Cholesterol Treatment Trialists C. Kearney P. M. Blackwell L. Collins R. Keech A. Simes J. Peto R. et al Efficacy of Cholesterol-Lowering Therapy in 18,686 People with Diabetes in 14 Randomised Trials of Statins: A Meta-Analysis. Lancet. 2008; 371(9607):117-25.doi.org/10.1016/S0140-6736(08)60104-X
10.    Khavandi M.  Duarte F.  Ginsberg H. N. Reyes-Soffer G. Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Curr Cardiol Rep. 2017; 19(1):7.doi.org/10.1007/s11886-017-0818-1
11.    Lotta L. A. Sharp S. J. Burgess S. Perry J. R. B. Stewart I. D. Willems S. M. Luan J. et al Association between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-Analysis. JAMA. 2016; 316(13):1383-91.doi.org/10.1001/jama.2016.14568
12.    Thakker D.  Nair S.  Pagada A.  Jamdade V. Malik A. Statin Use and the Risk of Developing Diabetes: A Network Meta-Analysis. Pharmacoepidemiol Drug Saf. 2016; 25(10):1131-49.doi.org/10.1002/pds.4020
13.    Betteridge D. J. Carmena R. The Diabetogenic Action of Statins - Mechanisms and Clinical Implications. Nat Rev Endocrinol. 2016; 12(2):99-110.doi.org/10.1038/nrendo.2015.194
14.    Chowdary R. P.  Praveen D. Aanandhi V. M. A Prospective Study on Incidence of Dyslipidemia in Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2017; 10(2):431-33.doi.org/
15.    Kalaivanan S.  Sarumathy S.  Ebens J. A.  Kumar K. N.  Parveen A. R. Ashraf M. N. Clinical Assessment and Comparison of Lipid Profiles among Coronary Artery Disease and Type 2 Diabetes Mellitus Patients Receiving Statin Therapy. Research Journal of Pharmacy and Technology. 2017; 10(1):18-20.doi.org/
16.    Vyasa B. Cardiovascular Death: Leading Cause of Death in Diabetes. Research Journal of Pharmacology and Pharmacodynamics. 2013; 5(4):249-56.doi.org/
17.    Kanase K.  Shinde N.  Bharti D.  Undale V. Bhosale A. Diabetes Macroangiopathy- A Review. Research Journal of Pharmacology and Pharmacodynamics. 2009; 1(2):45-49.doi.org/
18.    Panchal I.  Panigrahi B. Patel C. Recent Advancement Towards Treatment of Diabetes. Research Journal of Pharmacology and Pharmacodynamics. 2010; 2(1):12-22.doi.org/
19.    Biteker M.  Dayan A.  Can M. M.  Ilhan E.  Biteker F. S.  Tekkesin A. Duman D. Impaired Fasting Glucose Is Associated with Increased Perioperative Cardiovascular Event Rates in Patients Undergoing Major Non-Cardiothoracic Surgery. Cardiovasc Diabetol. 2011; 10:63.doi.org/10.1186/1475-2840-10-63
20.    Cai X. Zhang Y. Li M. Wu J. H. Mai L. Li J. Yang Y. et al Association between Prediabetes and Risk of All Cause Mortality and Cardiovascular Disease: Updated Meta-Analysis. BMJ. 2020; 370:m2297.doi.org/10.1136/bmj.m2297
21.    Ford E. S.  Zhao G. Li C. Pre-Diabetes and the Risk for Cardiovascular Disease: A Systematic Review of the Evidence. J Am Coll Cardiol. 2010; 55(13):1310-7.doi.org/10.1016/j.jacc.2009.10.060
22.    Ginsberg H. Statins in Cardiometabolic Disease: What Makes Pitavastatin Different? Cardiovasc Diabetol. 2013; 12 Suppl 1:S1.doi.org/10.1186/1475-2840-12-S1-S1
23.    Millan Nunez-Cortes J. Cases Amenos A. Ascaso Gimilio J. F. Barrios Alonso V. Pascual Fuster V. Pedro-Botet Montoya J. C. Pinto Sala X. et al Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the Diana Study. Am J Cardiovasc Drugs. 2017; 17(2):135-42.doi.org/10.1007/s40256-016-0197-9
24.    Zhao W. Zhao S. P. Different Effects of Statins on Induction of Diabetes Mellitus: An Experimental Study. Drug Des Devel Ther. 2015; 9:6211-23.doi.org/10.2147/DDDT.S87979
25.    Davidson M. H. Pharmacotherapy: Implications of High-Dose Statin Link with Incident Diabetes. Nat Rev Cardiol. 2011; 8(10):543-4.doi.org/10.1038/nrcardio.2011.118
26.    Preiss D. Seshasai S. R. Welsh P. Murphy S. A. Ho J. E. Waters D. D. DeMicco D. A. et al Risk of Incident Diabetes with Intensive-Dose Compared with Moderate-Dose Statin Therapy: A Meta-Analysis. JAMA. 2011; 305(24):2556-64.doi.org/10.1001/jama.2011.860
27.    Sattar N. Preiss D. Murray H. M. Welsh P. Buckley B. M. de Craen A. J. Seshasai S. R. et al Statins and Risk of Incident Diabetes: A Collaborative Meta-Analysis of Randomised Statin Trials. Lancet. 2010; 375(9716):735-42.doi.org/10.1016/S0140-6736(09)61965-6
28.    Mita T. Watada H. Nakayama S. Abe M. Ogihara T. Shimizu T. Uchino H. et al Preferable Effect of Pravastatin Compared to Atorvastatin on Beta Cell Function in Japanese Early-State Type 2 Diabetes with Hypercholesterolemia. Endocr J. 2007; 54(3):441-7.doi.org/10.1507/endocrj.k06-198
29.    Teramoto T.  Shimano H.  Yokote K. Urashima M. New Evidence on Pitavastatin: Efficacy and Safety in Clinical Studies. Expert Opin Pharmacother. 2010; 11(5):817-28.doi.org/10.1517/14656561003641990
30.    Yada T.  Nakata M.  Shiraishi T. Kakei M. Inhibition by Simvastatin, but Not Pravastatin, of Glucose-Induced Cytosolic Ca2+ Signalling and Insulin Secretion Due to Blockade of L-Type Ca2+ Channels in Rat Islet Beta-Cells. Br J Pharmacol. 1999; 126(5):1205-13.doi.org/10.1038/sj.bjp.0702397
31.    Kobayashi M. Chisaki I. Narumi K. Hidaka K. Kagawa T. Itagaki S. Hirano T. et al Association between Risk of Myopathy and Cholesterol-Lowering Effect: A Comparison of All Statins. Life Sci. 2008; 82(17-18):969-75.doi.org/10.1016/j.lfs.2008.02.019
32.    Velho J. A. Okanobo H. Degasperi G. R. Matsumoto M. Y. Alberici L. C. Cosso R. G. Oliveira H. C. et al Statins Induce Calcium-Dependent Mitochondrial Permeability Transition. Toxicology. 2006; 219(1-3):124-32.doi.org/10.1016/j.tox.2005.11.007
33.    Institute of Laboratory Animal R. National Research C. Guide for the Care and Use of Laboratory Animals. 2011; Washington:National Academy.
34.    Sadino A.  Muhtadi A.  Susilawati Y. Charisma S. L. Hypoglycemic Activity of Ethyl Acetate Fraction of Mengkudu Fruit (Morinda Citrifolia L.) in Mice Induced Alloxan. Research Journal of Pharmacy and Technology. 2019; 12(1):197-201.doi.org/
35.    Sarma B. Goswami B. C. Evaluation of Hypoglycemic Effect of Ethanol Extract of Musa Paradisiaca Unripe Fruit Pulp on Normal and Alloxan Induced Diabetic Mice. Research Journal of Pharmacy and Technology. 2018; 11(3):1048-52.doi.org/
36.    Kashyap M. L.  Tavintharan S. Kamanna V. S. Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol. American Journal of Cardiovascular Drugs. 2003; 3(1):53-65.doi.org/10.2165/00129784-200303010-00006
37.    Cederberg H.  Stančáková A.  Yaluri N.  Modi S.  Kuusisto J. Laakso M. Increased Risk of Diabetes with Statin Treatment Is Associated with Impaired Insulin Sensitivity and Insulin Secretion: A 6 year Follow-up Study of the Metsim Cohort. Diabetologia. 2015; 58(5):1109-17.doi.org/10.1007/s00125-015-3528-5
38.    Cho Y. Lee H. Park H. K. Choe E. Y. Wang H. J. Kim R. H. Kim Y. et al Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in Vitro and in Vivo. J Atheroscler Thromb. 2020; 27(5):429-40.doi.org/10.5551/jat.50039
39.    Yu Y. Ohmori K. Chen Y. Sato C. Kiyomoto H. Shinomiya K. Takeuchi H. et al Effects of Pravastatin on Progression of Glucose Intolerance and Cardiovascular Remodeling in a Type Ii Diabetes Model. J Am Coll Cardiol. 2004; 44(4):904-13.doi.org/10.1016/j.jacc.2004.04.050
40.    Kakuda H.  Kobayashi J.  Nakato M. Takekoshi N. Short-Term Effect of Pitavastatin Treatment on Glucose and Lipid Metabolism and Oxidative Stress in Fasting and Postprandial State Using a Test Meal in Japanese Men. Cholesterol. 2013; 2013:314170.doi.org/10.1155/2013/314170
41.    Lorza-Gil E. Salerno A. G. Wanschel A. C. Vettorazzi J. F. Ferreira M. S. Rentz T. Catharino R. R. et al Chronic Use of Pravastatin Reduces Insulin Exocytosis and Increases Beta-Cell Death in Hypercholesterolemic Mice. Toxicology. 2016; 344-346:42-52.doi.org/10.1016/j.tox.2015.12.007
42.    Kim J.  Lee H. S. Lee K. Y. Effect of Statins on Fasting Glucose in Non-Diabetic Individuals: Nationwide Population-Based Health Examination in Korea. Cardiovasc Diabetol. 2018; 17(1):155.doi.org/10.1186/s12933-018-0799-4
43.    Kanno H. Iwai M. Inaba S. Senba I. Nakaoka H. Sone H. Mogi M. et al Improvement of Glucose Intolerance by Combination of Pravastatin and Olmesartan in Type Ii Diabetic Kk-Ay Mice. Hypertension Research. 2009; 32(8):706-11.doi.org/10.1038/hr.2009.81
44.    Liu P. Y. Lin L. Y. Lin H. J. Hsia C. H. Hung Y. R. Yeh H. I. Wu T. C. et al Pitavastatin and Atorvastatin Double-Blind Randomized Comparative Study among High-Risk Patients, Including Those with Type 2 Diabetes Mellitus, in Taiwan (Papago-T Study). PLoS One. 2013; 8(10):e76298.doi.org/10.1371/journal.pone.0076298
45.    Hori E.  Kikuchi C.  Imaeda K.  Okayama N.  Suzuki T. Matsunaga T. [Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia]. Yakugaku Zasshi. 2019; 139(5):807-15.doi.org/10.1248/yakushi.18-00218
46.    Hara K. Horikoshi M. Yamauchi T. Yago H. Miyazaki O. Ebinuma H. Imai Y. et al Measurement of the High-Molecular Weight Form of Adiponectin in Plasma Is Useful for the Prediction of Insulin Resistance and Metabolic Syndrome. Diabetes Care. 2006; 29(6):1357-62.doi.org/10.2337/dc05-1801
47.    Kurogi K. Sugiyama S. Sakamoto K. Tayama S. Nakamura S. Biwa T. Matsui K. et al Comparison of Pitavastatin with Atorvastatin in Increasing Hdl-Cholesterol and Adiponectin in Patients with Dyslipidemia and Coronary Artery Disease: The Compact-Cad Study. J Cardiol. 2013; 62(2):87-94.doi.org/10.1016/j.jjcc.2013.03.008
48.    Matsubara T. Naruse K. Arakawa T. Nakao M. Yokoi K. Oguri M. Marui N. et al Impact of Pitavastatin on High-Sensitivity C-Reactive Protein and Adiponectin in Hypercholesterolemic Patients with the Metabolic Syndrome: The Premium Study. J Cardiol. 2012; 60(5):389-94.doi.org/10.1016/j.jjcc.2012.07.012
49.    Kim J. H. Lee M. R. Shin J. A. Lee S. S. Lee J. M. You S. J. Yoon K. H. et al Effects of Pravastatin on Serum Adiponectin Levels in Female Patients with Type 2 Diabetes Mellitus. Atherosclerosis. 2013; 227(2):355-9.doi.org/10.1016/j.atherosclerosis.2013.01.045
50.    Szkudelski T. The Mechanism of Alloxan and Streptozotocin Action in B Cells of the Rat Pancreas. Physiol Res. 2001; 50(6):537-46.doi.org/
51.    Baker W. L.  Talati R.  White C. M. Coleman C. I. Differing Effect of Statins on Insulin Sensitivity in Non-Diabetics: A Systematic Review and Meta-Analysis. Diabetes Research and Clinical Practice. 2010; 87(1):98-107.doi.org/10.1016/j.diabres.2009.10.008
52.    Lorza-Gil E.  García-Arevalo M.  Favero B. C.  Gomes-Marcondes M. C. C. Oliveira H. C. F. Diabetogenic Effect of Pravastatin Is Associated with Insulin Resistance and Myotoxicity in Hypercholesterolemic Mice. J Transl Med. 2019; 17(1):285.doi.org/10.1186/s12967-019-2045-6

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available